LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Relay Therapeutics Inc

Închisă

SectorSănătate

2.8 -0.36

Rezumat

Modificarea prețului

24h

Curent

Minim

2.72

Maxim

2.89

Indicatori cheie

By Trading Economics

Venit

-1.1M

-77M

Vânzări

7.7M

7.7M

EPS

-0.455

Marjă de profit

-1,003.581

Angajați

259

EBITDA

-1.2M

-85M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+401.79% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-21M

533M

Deschiderea anterioară

3.16

Închiderea anterioară

2.8

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Relay Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 19:39 UTC

Principalele dinamici ale pieței

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 mai 2025, 23:18 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mai 2025, 22:30 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- Update

16 mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mai 2025, 21:54 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mai 2025, 21:17 UTC

Top știri

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mai 2025, 20:55 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

16 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mai 2025, 20:37 UTC

Top știri

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mai 2025, 20:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mai 2025, 20:30 UTC

Achiziții, Fuziuni, Preluări

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mai 2025, 20:18 UTC

Top știri

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mai 2025, 20:16 UTC

Top știri

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mai 2025, 20:15 UTC

Câștiguri

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mai 2025, 20:11 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: William K. Daniel Joins Board

16 mai 2025, 20:10 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: Strategic Investment by KKR Completed

16 mai 2025, 20:05 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mai 2025, 18:51 UTC

Top știri

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mai 2025, 18:41 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 mai 2025, 18:35 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 18:32 UTC

Top știri

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparație

Modificare preț

Relay Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

401.79% sus

Prognoză pe 12 luni

Medie 14 USD  401.79%

Maxim 23 USD

Minim 4 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRelay Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

10

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.88 / 3.285Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.